Paul Chan
Primary Care · Orlando, FLNPI 1639603954
Payments from drug & device makers
Across 1,110 payments — averaging $403.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$232K
- Gilead$150K
- AbbVie$63K
- Viiv Healthcare Company$1K
- Merck$685
- Johnson & Johnson$223
- plus $401 from 9 others
What the payments were for
- Consulting fees$14,7233%
- Speaking & faculty fees$311,28870%
- Travel & lodging$100,97423%
- Food & beverage$20,4725%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 425 | $232,009 |
| Gilead | 375 | $149,999 |
| AbbVie | 180 | $62,798 |
| Viiv Healthcare Company | 70 | $1,342 |
| Merck | 33 | $685 |
| Johnson & Johnson | 8 | $223 |
| Theratechnologies Inc. | 7 | $154 |
| Lilly USA, LLC | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Novo Nordisk | 2 | $44 |
| EMD Serono, Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$447,457 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 64 | $137,626 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $46,027 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $44,020 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy | $149,999 | $181,64775 claims |
| Viiv Healthcare CompanyTriumeq | $1,342 | $46,02711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Orlando
- Katelyn VignolaOrlando$7K
- Jenny WestPensacola$80K
- Maria Rodriguez ReyesHialeah$31K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.